Congenital hepatic fibrosis in autosomal-dominant polycystic kidney disease.

Department of Medical Genetics, University of Groningen, The Netherlands.
Kidney International (Impact Factor: 8.52). 12/1990; 38(5):880-5. DOI: 10.1038/ki.1990.286
Source: PubMed

ABSTRACT Congenital hepatic fibrosis was found in four families with autosomal-dominant polycystic kidney disease. Congenital hepatic fibrosis is commonly though to be characteristic for autosomal-recessive polycystic kidney disease, but the reported families, show that it can also complicate autosomal-dominant polycystic kidney disease. In three families close linkage between the mutation causing the disease and DNA markers on chromosome 16 was demonstrated. The clinical course of the congenital hepatic fibrosis differed considerably; in one family the children with congenital hepatic fibrosis died soon after birth, in the three other families an approximately 20 years follow-up showed no detectable progression of the liver disease.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Advances in molecular genetics have led to the identification of more than 70 different genes involved in the development of cystic kidney diseases. Most of these diseases are rare, and interpreting the resultant plethora of disease-causing mutations requires a methodical and meticulous approach to differential diagnosis. In this Review we discuss a clinical approach to the diagnosis of cystic kidney diseases in adults, for use by nephrologists. This approach is based upon a thorough clinical evaluation, which considers both kidney phenotype and extrarenal manifestations of the underlying disorder, in combination with genetic testing in selected patients. In our view, cystic kidney disease can (in the majority of patients) be reliably classified on the basis of clinical findings. We therefore propose that defining clinical situations to precipitate the initiation of genetic testing is mandatory and cost-effective. New techniques such as next-generation sequencing will facilitate the diagnosis of cystic kidney diseases in the future, increasing diagnostic safety in a subset of patients. In renal tumour syndromes, genetic testing is warranted.
    Nature Reviews Nephrology 09/2014; DOI:10.1038/nrneph.2014.173 · 8.37 Impact Factor
  • Pediatric Pathology and Molecular Medicine 05/2001; 20(3):227-234. DOI:10.1080/15513810109168616
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intrahepatic bile ducts (IHBDs) develop from bi-potential liver progenitor cells in contact with themesenchyme of the portal vein and thus form the “ductal plates.” The ductal plates are remodeled into mature tubular ducts. Lack of remodeling results in the persistence of periportal epithelial sleeves or “ductal plate malformation” (DPM). A proposal is that virtually all congenital diseases of IHBDs represent examples of DPM. Some early, severe types of extra-hepatic bile duct atresia are characterized by DPM, a suggestion of a prenatal beginning of the disease. Several congenital diseases are characterized by dilatation of segments of IHBDs and variable degrees of fibrosis. Such “fibrocystic diseases” represent DPM at different levels of the biliary tree. Autosomal recessive polycystic kidney disease represents DPM of interlobular bile ducts, associated with tubular dilatation of collecting renal tubules. Congenital hepatic fibrosis may derive from the same type of liver lesion, through a superimposed destructive type of cholangiopathy associated with scarring fibrosis. Caroliapos;sdisease represents DPM of the larger IHBDs, whereas Caroliapos;s syndrome combines the lesions of Caroliapos;sdisease and congenital hepatic fibrosis, von Meyenburg complexes represent DPM of smaller interlobular ducts; their dilatation gives rise to the liver cysts in autosomal dominant polycystic kidney disease. Finally, DPM is a component of the tissue abnormalities in socalled mesenchymal hamartoma.
    Mayo Clinic Proceedings 01/1998; 73(1):80-89. DOI:10.1016/S0025-6196(11)63624-0 · 5.81 Impact Factor